Skip to content
DataLookout
Menu

NCT03971461

Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 16 versions: 14 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 17, 2026
    • Secondary endpoints: 4 to 2
    • Primary endpoint revised
  2. Notable Eligibility criteria expanded, about 40 words
    • Secondary endpoints: details revised at 2 of 4 entries
  3. Minor Primary completion date changed from estimate of Jan 2026 to Apr 18, 2025v14
  4. Notable Primary completion date: Feb 2025 to Jan 2026
    • Study completion date: Feb 2026 to Jan 2027
    v13
  5. Notable Primary completion date: May 2024 to Feb 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: May 2025 to Feb 2026
    • Site details revised at 2 of 2 sites
    v12
Show 8 earlier versionsHide 8 earlier versions
  1. Notable Primary completion date: May 2022 to May 2024
    • Study completion date: May 2023 to May 2025
    v10
  2. Minor Site contacts updated at 1 of 2 sitesv9
  3. Minor Study sites: 1 to 2v8
  4. Minor Site contact updatedv7
  5. Notable Primary completion date: May 2020 to May 2022
    • Eligibility criteria expanded, about 179 words
    • Study completion date: May 2020 to May 2023
    v5
  6. Minor Site contact updatedv4
  7. Minor Site contact updatedv3
  8. Minor Study title shortened, about 5 wordsv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression Free Survival at 6 Months (PFS-6)
Timeframe: 6 Months

Secondary (2)

Overall Survival at 12 Months (OS-12)
Overall Survival (OS)

Arms and interventions

LutatheraExperimental

Drugs: Lutathera

Sites

2 sites in 1 country